PF-00835231 is a potent and selective inhibitor of the SARS-CoV-2 3CL protease, demonstrating sub-nanomolar in vitro activity. As the active moiety of the first 3CLpro-targeting clinical candidate, it serves as a crucial research tool for studying coronavirus replication and for the development of antiviral therapeutics in both biochemical and cellular assays.